

# Veterinary Dermatology - Company Evaluation Report, 2025

<https://marketpublishers.com/r/VB09BDEA5348EN.html>

Date: May 2025

Pages: 142

Price: US\$ 2,650.00 (Single User License)

ID: VB09BDEA5348EN

## Abstracts

The Veterinary Dermatology Market Companies Quadrant is a comprehensive industry analysis that provides valuable insights into the global market for Veterinary Dermatology Market . This quadrant offers a detailed evaluation of key market players, technological advancements, product innovations, and emerging trends shaping the industry. MarketsandMarkets 360 Quadrants evaluated over 100 companies, of which the Top 25 Veterinary Dermatology Market Companies were categorized and recognized as the quadrant leaders.

The veterinary dermatology market, focused on products for preventing and treating dermatological diseases in animals, is projected to grow from USD 20.11 billion in 2025 to USD 30.31 billion by 2030, at a CAGR of 8.5%. This growth is driven by factors such as the increasing companion animal population, rising pet ownership, concerns about zoonotic diseases, and awareness campaigns by government and animal welfare organizations. Despite these drivers, the high cost of pet care may limit adoption of veterinary dermatology products. Additionally, the growth of the market is supported by advancements in veterinary technology and an increase in the number of veterinary practitioners, although challenges like parasite species diversity and resistance to parasiticides remain significant hurdles.

The veterinary dermatology market is segmented by route of administration, product type, condition type, and animal type. In 2024, the topical segment led the market with 61.5% of the share, driven by ease of application and rapid action. The oral segment is expected to grow the fastest due to its long-lasting effects and high compliance among pet owners. By product type, antiparasitic drugs held the largest share at 47.4%, largely due to the high prevalence of parasitic infections in both companion and livestock animals. In terms of condition type, parasitic infections dominated with 54.1% of the

market share. The companion animal segment accounted for the largest share by animal type, with 80.8%, reflecting the rising pet adoption rate and increasing spending on pet care. Market growth is expected to be driven by rising pet ownership, awareness, and technological advancements in veterinary dermatology treatments.

The 360 Quadrant maps the Veterinary Dermatology Market companies based on criteria such as revenue, geographic presence, growth strategies, investments, and sales strategies for the market presence of the Veterinary Dermatology Market quadrant. The top criteria for product footprint evaluation included Route of administration (Topical, Injectables, Oral), By Product type (antiparasitic drugs, antifungal drugs, antibacterial drugs, monoclonal antibodies, other product types) By Condition Type (parasitic infections, infectious diseases, autoimmune skin diseases, skin cancer) By Animal Type (companion animals, livestock animals) By End user (veterinary hospitals and clinics, animal shelters and rescues).

### **Key Players:**

Key market players, such as Elanco Animal Health Incorporated (US), Merck & Co., Inc. (US), Virbac (France), Zoetis Inc. (US), Boehringer Ingelheim International GmbH (Germany), Vetoquinol (France), Dechra Pharmaceuticals plc (UK), Hester Biosciences Limited (India), PetIQ, Inc. (US), Ourofino Saude Animal (Brazil), Swedencare (Sweden), Orion Corporation (Finland), Norbrook (Ireland), Ceva Sante Animale (France), and Bimeda, Inc. (Ireland). The other players in the veterinary dermatology market are Indian Immunologicals Ltd. (India), Vetanco (Brazil), Chanelle Pharma (Ireland), Pegasus Laboratories, Inc. (US), Kyoritsu Seiyaku Corporation (China), AVet Health (Australia), Animalderma Srls (Italy), LETI Pharma (Spain), Huvepharma, Inc. (Bulgaria), and VetPlus (UK).

### **Zoetis Inc.**

Zoetis Inc. stands out as a leading player in the animal health domain, providing extensive dermatological solutions through both its Companion Animal and Livestock divisions. Operating across 70 countries, Zoetis offers a diversified product range including topical, injectable, and oral formulations targeting various skin conditions in pets and farm animals. The company maintains a noteworthy global distribution network, demonstrating strong market positioning and a competitive edge by leveraging strategic partnerships and continuous product development.

### **Elanco Animal Health Incorporated**

Elanco Animal Health excels in offering a diverse portfolio focused on disease prevention and treatment across pet and farm animal categories. The company's commitment to innovation is reflected in its extensive global operations and strategic acquisitions, such as the integration of Bayer Animal Health. Headquartered in Greenfield, Indiana, Elanco emphasizes product innovation and maintains strong market positions through its presence in over 90 countries.

### **Boehringer Ingelheim International GmbH**

Boehringer Ingelheim is a prominent multinational pharmaceutical firm with a robust Animal Health division, known for its innovative dermatological solutions. The company maintains a dominant market position by offering a wide array of products catering to both companion and farm animals. Its expansive geographic reach is supported by a network of 146 subsidiaries, ensuring a strong foothold in the veterinary dermatology market. Boehringer Ingelheim's strategic investments in R&D bolster its competitive stance, focusing on innovative treatments and enhanced product efficacy.

## Contents

### **1 INTRODUCTION**

- 1.1 MARKET DEFINITION
- 1.2 INCLUSIONS AND EXCLUSIONS
- 1.3 STAKEHOLDERS

### **2 EXECUTIVE SUMMARY**

### **3 MARKET OVERVIEW**

#### 3.1 INTRODUCTION

#### 3.2 MARKET DYNAMICS

##### 3.2.1 DRIVERS

- 3.2.1.1 Expanding companion animal population and pet ownership
- 3.2.1.2 Growing concerns about infectious zoonotic diseases
- 3.2.1.3 Rising awareness initiatives by government and animal welfare organizations
- 3.2.1.4 Increasing adoption of pet insurance and high animal healthcare expenditure

##### 3.2.2 RESTRAINTS

- 3.2.2.1 Rising pet care costs
- 3.2.2.2 Restrictions on use of parasiticides for food-producing animals

##### 3.2.3 OPPORTUNITIES

- 3.2.3.1 Technological advancements and product launches
- 3.2.3.2 High growth potential in emerging economies
- 3.2.3.3 Surging number of veterinary practitioners in developed markets

##### 3.2.4 CHALLENGES

- 3.2.4.1 Growing resistance to parasiticides
- 3.2.4.2 Diversity in parasite species

#### 3.3 INDUSTRY TRENDS

##### 3.3.1 RISE IN PET OWNERSHIP, HUMANIZATION OF PETS, AND INCREASED FOCUS ON PET WELLNESS PROGRAMS

##### 3.3.2 RISING USE OF DIAGNOSTICS AND WEARABLE TECHNOLOGY FOR EARLY DETECTION

#### 3.4 TECHNOLOGY ANALYSIS

##### 3.4.1 KEY TECHNOLOGIES

- 3.4.1.1 Topical nanomedicine
- 3.4.1.2 Biologic therapies

##### 3.4.2 COMPLEMENTARY TECHNOLOGIES

- 3.4.2.1 Phototherapy
- 3.4.2.2 Hydrotherapy
- 3.4.3 ADJACENT TECHNOLOGIES
  - 3.4.3.1 Telemedicine platforms
  - 3.4.3.2 Wearable devices
- 3.5 PORTER'S FIVE FORCES ANALYSIS
  - 3.5.1 COMPETITIVE RIVALRY
    - 3.5.1.1 Established players
    - 3.5.1.2 Continuous innovation
  - 3.5.2 BARGAINING POWER OF BUYERS
    - 3.5.2.1 Consolidated veterinary groups
    - 3.5.2.2 Demand for affordable solutions
  - 3.5.3 BARGAINING POWER OF SUPPLIERS
    - 3.5.3.1 Specialized raw materials
    - 3.5.3.2 Quality compliance
  - 3.5.4 THREAT OF SUBSTITUTES
    - 3.5.4.1 Limited alternatives
    - 3.5.4.2 Specialized treatments
  - 3.5.5 THREAT OF NEW ENTRANTS
    - 3.5.5.1 High R&D costs
    - 3.5.5.2 Regulatory requirements
- 3.6 PATENT ANALYSIS
  - 3.6.1 PATENT PUBLICATION TRENDS FOR VETERINARY DERMATOLOGY MARKET
  - 3.6.2 INSIGHTS: JURISDICTION AND TOP APPLICANT ANALYSIS
- 3.7 KEY CONFERENCES AND EVENTS
- 3.8 IMPACT OF GENERATIVE AI ON VETERINARY DERMATOLOGY MARKET
- 3.9 ECOSYSTEM ANALYSIS
- 3.10 SUPPLY CHAIN ANALYSIS
- 3.11 VALUE CHAIN ANALYSIS
- 3.12 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS

## **4 COMPETITIVE LANDSCAPE**

- 4.1 OVERVIEW
- 4.2 KEY PLAYER STRATEGY/RIGHT TO WIN
- 4.3 REVENUE ANALYSIS OF KEY PLAYERS IN VETERINARY DERMATOLOGY MARKET (2020–2024)
- 4.4 MARKET SHARE ANALYSIS, 2024

- 4.4.1 RANKING OF KEY MARKET PLAYERS, 2024
- 4.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024
  - 4.5.1 STARS
  - 4.5.2 EMERGING LEADERS
  - 4.5.3 PERVASIVE PLAYERS
  - 4.5.4 PARTICIPANTS
  - 4.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2024
    - 4.5.5.1 Company footprint
    - 4.5.5.2 Region footprint
    - 4.5.5.3 Route of administration footprint
    - 4.5.5.4 Product type footprint
    - 4.5.5.5 Condition type footprint
    - 4.5.5.6 Animal type footprint
- 4.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024
  - 4.6.1 PROGRESSIVE COMPANIES
  - 4.6.2 RESPONSIVE COMPANIES
  - 4.6.3 DYNAMIC COMPANIES
  - 4.6.4 STARTING BLOCKS
  - 4.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2024
- 4.7 BRAND/PRODUCT COMPARISON
- 4.8 R&D EXPENDITURE OF KEY PLAYERS
- 4.9 COMPANY VALUATION AND FINANCIAL METRICS
  - 4.9.1 COMPANY VALUATION
  - 4.9.2 FINANCIAL METRICS
- 4.10 COMPETITIVE SCENARIO
  - 4.10.1 PRODUCT APPROVALS/LAUNCHES
  - 4.10.2 DEALS
  - 4.10.3 EXPANSIONS
  - 4.10.4 OTHER DEVELOPMENTS

## **5 COMPANY PROFILES**

- 5.1 KEY PLAYERS
  - 5.1.1 ELANCO ANIMAL HEALTH INCORPORATED
    - 5.1.1.1 Business overview
    - 5.1.1.2 Products offered
    - 5.1.1.3 Recent developments
      - 5.1.1.3.1 Product launches and approvals
      - 5.1.1.3.2 Deals

- 5.1.1.3.3 Expansions
- 5.1.1.4 MnM view
  - 5.1.1.4.1 Right to win
  - 5.1.1.4.2 Strategic choices
  - 5.1.1.4.3 Weaknesses and competitive threats
- 5.1.2 MERCK & CO., INC
  - 5.1.2.1 Business overview
  - 5.1.2.2 Products offered
  - 5.1.2.3 Recent developments
    - 5.1.2.3.1 Product launches and approvals
    - 5.1.2.3.2 Deals
    - 5.1.2.3.3 Expansions
    - 5.1.2.3.4 Other developments
  - 5.1.2.4 MnM view
    - 5.1.2.4.1 Right to win
    - 5.1.2.4.2 Strategic choices
    - 5.1.2.4.3 Weaknesses and competitive threats
- 5.1.3 VIRBAC
  - 5.1.3.1 Business overview
  - 5.1.3.2 Products offered
  - 5.1.3.3 Recent developments
    - 5.1.3.3.1 Deals
    - 5.1.3.3.2 Expansions
    - 5.1.3.3.3 Other developments
  - 5.1.3.4 MnM view
    - 5.1.3.4.1 Right to win
    - 5.1.3.4.2 Strategic choices
    - 5.1.3.4.3 Weaknesses and competitive threats
- 5.1.4 ZOETIS INC.
  - 5.1.4.1 Business overview
  - 5.1.4.2 Products offered
  - 5.1.4.3 Recent developments
    - 5.1.4.3.1 Product launches and approvals
    - 5.1.4.3.2 Deals
    - 5.1.4.3.3 Expansions
    - 5.1.4.3.4 Other developments
  - 5.1.4.4 MnM view
    - 5.1.4.4.1 Right to win
    - 5.1.4.4.2 Strategic choices

- 5.1.4.4.3 Weaknesses and competitive threats
- 5.1.5 BOEHRINGER INGELHEIM INTERNATIONAL GMBH
  - 5.1.5.1 Business overview
  - 5.1.5.2 Products offered
  - 5.1.5.3 Recent developments
    - 5.1.5.3.1 Product approvals
    - 5.1.5.3.2 Deals
  - 5.1.5.4 MnM view
    - 5.1.5.4.1 Right to win
    - 5.1.5.4.2 Strategic choices
    - 5.1.5.4.3 Weaknesses and competitive threats
- 5.1.6 VETOQUINOL
  - 5.1.6.1 Business overview
  - 5.1.6.2 Products offered
  - 5.1.6.3 Recent developments
    - 5.1.6.3.1 Product approvals
- 5.1.7 DECHRA PHARMACEUTICALS PLC
  - 5.1.7.1 Business overview
  - 5.1.7.2 Products offered
  - 5.1.7.3 Recent developments
    - 5.1.7.3.1 Product approvals
    - 5.1.7.3.2 Deals
- 5.1.8 HESTER BIOSCIENCES LIMITED
  - 5.1.8.1 Business overview
  - 5.1.8.2 Products offered
- 5.1.9 PETIQ, INC.
  - 5.1.9.1 Business overview
  - 5.1.9.2 Products offered
  - 5.1.9.3 Recent developments
    - 5.1.9.3.1 Other developments
- 5.1.10 OUROFINO SAUDE ANIMAL
  - 5.1.10.1 Business overview
  - 5.1.10.2 Products offered
- 5.1.11 SWEDENCARE
  - 5.1.11.1 Business overview
  - 5.1.11.2 Products offered
  - 5.1.11.3 Recent developments
    - 5.1.11.3.1 Deals
- 5.1.12 ORION CORPORATION



5.1.12.1 Business overview

5.1.12.2 Products offered

#### 5.1.13 NORBROOK

5.1.13.1 Business overview

5.1.13.2 Products offered

5.1.13.3 Recent developments

5.1.13.3.1 Product launches

5.1.13.3.2 Expansions

#### 5.1.14 CEVA SANTE ANIMALE

5.1.14.1 Business overview

5.1.14.2 Products offered

5.1.14.3 Recent developments

5.1.14.3.1 Deals

#### 5.1.15 BIMEDA, INC.

5.1.15.1 Business overview

5.1.15.2 Products offered

5.1.15.3 Recent developments

5.1.15.3.1 Product launches

5.1.15.3.2 Deals

### 5.2 OTHER PLAYERS

5.2.1 INDIAN IMMUNOLOGICALS LTD.

5.2.2 VETANCO

5.2.3 CHANELLE PHARMA

5.2.4 PEGASUS LABORATORIES, INC.

5.2.5 KYORITSU SEIYAKU CORPORATION

5.2.6 AVET HEALTH

5.2.7 ANIMALDERMA SRLS

5.2.8 LETI PHARMA

5.2.9 HUVEPHARMA, INC.

5.2.10 VETPLUS

## 6 APPENDIX

### 6.1 RESEARCH METHODOLOGY

6.1.1 RESEARCH APPROACH

6.1.1.1 Secondary data

6.1.1.2 Primary data

6.1.2 RESEARCH ASSUMPTIONS

6.1.3 RISK ASSESSMENT

6.1.4 RESEARCH LIMITATIONS	
6.2 COMPANY EVALUATION MATRIX: METHODOLOGY	
6.3 AUTHOR DETAILS	

## List Of Tables

### LIST OF TABLES

TABLE 1 PET (DOGS AND CATS) OWNERSHIP STATISTICS IN US, 2024
TABLE 2 COMPANION ANIMAL POPULATION STATISTICS, BY REGION
TABLE 3 MAJOR OUTBREAKS OF ZOO NOTIC DISEASES, 2022–2023
TABLE 4 AVERAGE ANNUAL PREMIUM: US AND CANADA (USD)
TABLE 5 VETERINARY DERMATOLOGY MARKET: IMPACT OF PORTER’S FIVE FORCES ANALYSIS
TABLE 6 VETERINARY DERMATOLOGY MARKET: LIST OF MAJOR PATENTS
TABLE 7 VETERINARY DERMATOLOGY MARKET: KEY CONFERENCES AND EVENTS (2025?2026)
TABLE 8 VETERINARY DERMATOLOGY MARKET: IMPACT OF GENERATIVE AI
TABLE 9 VETERINARY DERMATOLOGY MARKET: ROLE OF COMPANIES IN ECOSYSTEM
TABLE 10 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN VETERINARY DERMATOLOGY MARKET
TABLE 11 VETERINARY DERMATOLOGY MARKET: DEGREE OF COMPETITION
TABLE 12 VETERINARY DERMATOLOGY MARKET: REGION FOOTPRINT
TABLE 13 VETERINARY DERMATOLOGY MARKET: ROUTE OF ADMINISTRATION FOOTPRINT
TABLE 14 VETERINARY DERMATOLOGY MARKET: PRODUCT TYPE FOOTPRINT
TABLE 15 VETERINARY DERMATOLOGY MARKET: CONDITION TYPE FOOTPRINT
TABLE 16 VETERINARY DERMATOLOGY MARKET: ANIMAL TYPE FOOTPRINT
TABLE 17 VETERINARY DERMATOLOGY MARKET: LIST OF KEY STARTUPS/SMES
TABLE 18 VETERINARY DERMATOLOGY MARKET: COMPETITIVE BENCHMARKING OF STARTUPS/SMES
TABLE 19 VETERINARY DERMATOLOGY MARKET: PRODUCT APPROVALS/LAUNCHES, JANUARY 2021–JANUARY 2025
TABLE 20 VETERINARY DERMATOLOGY MARKET: DEALS, JANUARY 2021–JANUARY 2025
TABLE 21 VETERINARY DERMATOLOGY MARKET: EXPANSIONS, JANUARY 2021–JANUARY 2025
TABLE 22 VETERINARY DERMATOLOGY MARKET: OTHER DEVELOPMENTS, JANUARY 2021–JANUARY 2025
TABLE 23 ELANCO ANIMAL HEALTH INCORPORATED: COMPANY OVERVIEW
TABLE 24 ELANCO ANIMAL HEALTH INCORPORATED: PRODUCTS OFFERED

TABLE 25 ELANCO ANIMAL HEALTH INCORPORATED: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2021–JANUARY 2025

TABLE 26 ELANCO ANIMAL HEALTH INCORPORATED: DEALS, JANUARY 2021–JANUARY 2025

TABLE 27 ELANCO ANIMAL HEALTH INCORPORATED: EXPANSIONS, JANUARY 2021–JANUARY 2025

TABLE 28 MERCK & CO., INC: COMPANY OVERVIEW

TABLE 29 MERCK & CO., INC: PRODUCTS OFFERED

TABLE 30 MERCK & CO., INC: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2021–JANUARY 2025

TABLE 31 MERCK & CO., INC: DEALS, JANUARY 2021–JANUARY 2025

TABLE 32 MERCK & CO., INC: EXPANSIONS, JANUARY 2021–JANUARY 2025

TABLE 33 MERCK & CO., INC: OTHER DEVELOPMENTS, JANUARY 2021–JANUARY 2025

TABLE 34 VIRBAC: COMPANY OVERVIEW

TABLE 35 VIRBAC: PRODUCTS OFFERED

TABLE 36 VIRBAC: DEALS, JANUARY 2021–JANUARY 2025

TABLE 37 VIRBAC: EXPANSIONS, JANUARY 2021–JANUARY 2025

TABLE 38 VIRBAC: OTHER DEVELOPMENTS, JANUARY 2021–JANUARY 2025

TABLE 39 ZOETIS INC.: COMPANY OVERVIEW

TABLE 40 ZOETIS INC.: PRODUCTS OFFERED

TABLE 41 ZOETIS INC.: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2021–JANUARY 2025

TABLE 42 ZOETIS INC.: DEALS, JANUARY 2021–JANUARY 2025

TABLE 43 ZOETIS INC.: EXPANSIONS, JANUARY 2021–JANUARY 2025

TABLE 44 ZOETIS INC.: OTHER DEVELOPMENTS, JANUARY 2021–JANUARY 2025

TABLE 45 BOEHRINGER INGELHEIM INTERNATIONAL GMBH: COMPANY OVERVIEW

TABLE 46 BOEHRINGER INGELHEIM INTERNATIONAL GMBH: PRODUCTS OFFERED

TABLE 47 BOEHRINGER INGELHEIM INTERNATIONAL GMBH: PRODUCT APPROVALS, JANUARY 2021–JANUARY 2025

TABLE 48 BOEHRINGER INGELHEIM INTERNATIONAL GMBH: DEALS, JANUARY 2021–JANUARY 2025

TABLE 49 VETOQUINOL: COMPANY OVERVIEW

TABLE 50 VETOQUINOL: PRODUCTS OFFERED

TABLE 51 VETOQUINOL: PRODUCT APPROVALS, JANUARY 2021–JANUARY 2025

TABLE 52 DECHRA PHARMACEUTICALS PLC: COMPANY OVERVIEW

TABLE 53 DECHRA PHARMACEUTICALS PLC: PRODUCTS OFFERED

TABLE 54 DECHRA PHARMACEUTICALS PLC: PRODUCT APPROVALS, JANUARY 2021–JANUARY 2025

TABLE 55 DECHRA PHARMACEUTICALS PLC: DEALS, JANUARY 2021–JANUARY 2025

TABLE 56 HESTER BIOSCIENCES LIMITED: COMPANY OVERVIEW

TABLE 57 HESTER BIOSCIENCES LIMITED: PRODUCTS OFFERED

TABLE 58 PETIQ, INC.: COMPANY OVERVIEW

TABLE 59 PETIQ, INC.: PRODUCTS OFFERED

TABLE 60 PETIQ, INC.: OTHER DEVELOPMENTS, JANUARY 2021–JANUARY 2025

TABLE 61 OUROFINO SAUDE ANIMAL: COMPANY OVERVIEW

TABLE 62 OUROFINO SAUDE ANIMAL: PRODUCTS OFFERED

TABLE 63 SWEDENCARE: COMPANY OVERVIEW

TABLE 64 SWEDENCARE: PRODUCTS OFFERED

TABLE 65 SWEDENCARE: DEALS, JANUARY 2021–JANUARY 2025

TABLE 66 ORION CORPORATION: COMPANY OVERVIEW

TABLE 67 ORION CORPORATION: PRODUCTS OFFERED

TABLE 68 NORBROOK: COMPANY OVERVIEW

TABLE 69 NORBROOK: PRODUCTS OFFERED

TABLE 70 NORBROOK: PRODUCT LAUNCHES, JANUARY 2021–JANUARY 2025

TABLE 71 NORBROOK: EXPANSIONS, JANUARY 2021–JANUARY 2025

TABLE 72 CEVA SANTE ANIMALE: COMPANY OVERVIEW

TABLE 73 CEVA SANTE ANIMALE: PRODUCTS OFFERED

TABLE 74 CEVA SANTE ANIMALE: DEALS, JANUARY 2021–JANUARY 2025

TABLE 75 BIMEDA, INC.: COMPANY OVERVIEW

TABLE 76 BIMEDA, INC.: PRODUCTS OFFERED

TABLE 77 BIMEDA, INC.: PRODUCT LAUNCHES, JANUARY 2021–JANUARY 2025

TABLE 78 BIMEDA, INC.: DEALS, JANUARY 2021–JANUARY 2025

## List Of Figures

### LIST OF FIGURES

FIGURE 1 VETERINARY DERMATOLOGY MARKET, BY ROUTE OF ADMINISTRATION, 2025 VS. 2030 (USD MILLION)

FIGURE 2 VETERINARY DERMATOLOGY MARKET, BY PRODUCT, 2025 VS. 2030 (USD MILLION)

FIGURE 3 VETERINARY DERMATOLOGY MARKET, BY CONDITION TYPE, 2025 VS. 2030 (USD MILLION)

FIGURE 4 VETERINARY DERMATOLOGY MARKET, BY ANIMAL TYPE, 2025 VS. 2030 (USD MILLION)

FIGURE 5 VETERINARY DERMATOLOGY MARKET FOR COMPANION ANIMALS, 2025 VS. 2030 (USD MILLION)

FIGURE 6 VETERINARY DERMATOLOGY MARKET FOR LIVESTOCK ANIMALS, 2025 VS. 2030 (USD MILLION)

FIGURE 7 VETERINARY DERMATOLOGY MARKET, BY END USER, 2025 VS. 2030 (USD MILLION)

FIGURE 8 GEOGRAPHIC SNAPSHOT: ASIA PACIFIC TO WITNESS HIGHEST GROWTH RATE DURING FORECAST PERIOD

FIGURE 9 VETERINARY DERMATOLOGY MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES

FIGURE 10 PET POPULATION IN MAJOR MARKETS IN 2022 (MILLION)

FIGURE 11 EUROPE: PET POPULATION, 2021–2023

FIGURE 12 TOTAL INSURED PETS IN US, 2019–2023

FIGURE 13 TOTAL INSURED PETS IN CANADA, 2019–2023

FIGURE 14 TOTAL NUMBER OF VETERINARIANS IN US, BY GENDER, 2020–2023

FIGURE 15 NUMBER OF VETERINARIANS IN TOP 5 EUROPEAN COUNTRIES, 2023

FIGURE 16 VETERINARY DERMATOLOGY MARKET: PORTER'S FIVE FORCES ANALYSIS

FIGURE 17 PATENT PUBLICATION TRENDS, JANUARY 2014–DECEMBER 2024

FIGURE 18 TOP APPLICANTS AND OWNERS (COMPANIES/INSTITUTIONS) FOR VETERINARY DERMATOLOGY PATENTS (JANUARY 2014–DECEMBER 2024)

FIGURE 19 TOP APPLICANT COUNTRIES/REGIONS FOR VETERINARY DERMATOLOGY PATENTS (JANUARY 2014–DECEMBER 2024)

FIGURE 20 VETERINARY DERMATOLOGY MARKET: ECOSYSTEM ANALYSIS

FIGURE 21 VETERINARY DERMATOLOGY MARKET: SUPPLY CHAIN ANALYSIS

FIGURE 22 VETERINARY DERMATOLOGY MARKET: VALUE CHAIN ANALYSIS

FIGURE 23 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS IN VETERINARY DERMATOLOGY MARKET

FIGURE 24 REVENUE ANALYSIS OF KEY PLAYERS IN VETERINARY DERMATOLOGY MARKET (2020?2024)

FIGURE 25 SHARE ANALYSIS OF KEY PLAYERS IN VETERINARY DERMATOLOGY MARKET (2024)

FIGURE 26 RANKING OF KEY PLAYERS IN VETERINARY DERMATOLOGY MARKET, 2024

FIGURE 27 VETERINARY DERMATOLOGY MARKET: COMPANY EVALUATION MATRIX, 2024

FIGURE 28 VETERINARY DERMATOLOGY MARKET: COMPANY FOOTPRINT, 2024

FIGURE 29 VETERINARY DERMATOLOGY MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2024

FIGURE 30 VETERINARY DERMATOLOGY MARKET: BRAND/PRODUCT COMPARATIVE ANALYSIS

FIGURE 31 R&D EXPENDITURE OF KEY PLAYERS IN VETERINARY DERMATOLOGY MARKET, 2021?2023

FIGURE 32 EV/EBITDA FOR TOP COMPANIES

FIGURE 33 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS

FIGURE 34 ELANCO ANIMAL HEALTH INCORPORATED: COMPANY SNAPSHOT (2024)

FIGURE 35 MERCK & CO., INC: COMPANY SNAPSHOT (2024)

FIGURE 36 VIRBAC: COMPANY SNAPSHOT (2023)

FIGURE 37 ZOETIS INC.: COMPANY SNAPSHOT (2024)

FIGURE 38 BOEHRINGER INGELHEIM INTERNATIONAL GMBH: COMPANY SNAPSHOT (2023)

FIGURE 39 VETOQUINOL: COMPANY SNAPSHOT (2023)

FIGURE 40 DECHRA PHARMACEUTICALS PLC: COMPANY SNAPSHOT (2023)

FIGURE 41 HESTER BIOSCIENCES LIMITED: COMPANY SNAPSHOT (2023)

FIGURE 42 PETIQ, INC.: COMPANY SNAPSHOT (2023)

FIGURE 43 OUROFINO SAUDE ANIMAL: COMPANY SNAPSHOT (2023)

FIGURE 44 SWEDENCARE: COMPANY SNAPSHOT (2023)

FIGURE 45 ORION CORPORATION: COMPANY SNAPSHOT (2023)

FIGURE 46 NORBROOK: COMPANY SNAPSHOT (2023)

FIGURE 47 RESEARCH DESIGN

## I would like to order

Product name: Veterinary Dermatology - Company Evaluation Report, 2025

Product link: <https://marketpublishers.com/r/VB09BDEA5348EN.html>

Price: US\$ 2,650.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/VB09BDEA5348EN.html>